The milestone was reached on the transition of an oncology programme into lead optimisation.
The collaboration was made for jointly indentifying and developing preclinical development candidates for the treatment of various disease areas including CNS, inflammation, cardiometabolic and respiratory diseases.
The agreement was extended in 2009 for an additional four years and the scope expanded to include oncology targets.
Under the terms of the agreement, Boehringer Ingelheim has full ownership and global responsibility for clinical development, manufacturing and commercialisation of the compounds identified.
Evotec chief operating officer Mario Polywka said this is the eleventh milestone achieved as part of this alliance with Boehringer Ingelheim and the second against an oncology target.